You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

IL-4 Contributes to Systemic Type 2 Inflammation in AD

In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.

Stephan Weidinger
MD, PhD
Stephan Weidinger

Learning objectives

  • • Explore how type 2 cytokines, including IL-4, contribute to systemic type 2 inflammation in AD
Tags
symposium
MAT-GLB-2406718 - 3.0 - 02/2025

About this expert

Dermatology

Stephan Weidinger

MD, PhD

Professor and Chair for Dermatology at the Christian-Albrechts-University; Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, Campus Kiel, Germany

See author’s profile
Stephan Weidinger

Related resources

What is Early Intervention in AD?
Dermatology
expert video

What is Early Intervention in AD?

Disease Modification in AD
Dermatology
expert video

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin
Dermatology
expert video

Systemic Inflammation in AD – Beyond the Skin

Dysbiosis, Skin Infections, and Itch
Dermatology
expert video

Dysbiosis, Skin Infections, and Itch

Skin Barrier Dysfunction in AD
Dermatology
expert video

Skin Barrier Dysfunction in AD

Early Intervention and the Potential for Disease Modification in Children With AD
Dermatology
expert video

Early Intervention and the Potential for Disease Modification in Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD
Dermatology
expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
Dermatology
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

Skin Dysbiosis in AD
Dermatology
expert video

Skin Dysbiosis in AD

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch
Dermatology
expert video

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

The Impact of Skin Dysbiosis on Atopic Dermatitis
Dermatology
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD
Dermatology
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers
Dermatology
expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

Barrier Tight Junction Disruption in Atopic Dermatitis
Dermatology
expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 

The Burden of Atopic Dermatitis in Children – Bullying in School
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Bullying in School

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

The Role of Epithelial Barrier Components in AD: Insights and Implications
Dermatology
expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD
Dermatology
expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

The Potential Impact of Early Intervention in Atopic Dermatitis in Children
Dermatology
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
Dermatology
expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

Managing Injection Pain in Children
Dermatology
expert video

Managing Injection Pain in Children

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN
Dermatology
expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

Key Type 2 Cytokines Impact Skin Structural Proteins in Atopic Dermatitis
Dermatology
expert video

Key Type 2 Cytokines Impact Skin Structural Proteins in Atopic Dermatitis

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis
Dermatology
expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

The Role of Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
Dermatology
expert video

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

High Burden of Atopic Dermatitis in Children
Dermatology
expert video

High Burden of Atopic Dermatitis in Children

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers
Dermatology
expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

Most Children With Atopic Dermatitis Have Uncontrolled Disease
Dermatology
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management
Dermatology
expert video

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children
Dermatology
expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

Current Treatment Landscape and Emerging Therapies
Dermatology
expert video

Current Treatment Landscape and Emerging Therapies

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Dermatology
Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health
Dermatology
expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD
Dermatology
expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

How Can We Explore the Concept of Disease Modification in Children With AD?
Dermatology
expert video

How Can We Explore the Concept of Disease Modification in Children With AD?

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU
Dermatology
expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

Differences in Itch in AD, PN, and CSU
Dermatology
expert video

Differences in Itch in AD, PN, and CSU

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 
Dermatology
expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Itch in AD, PN and CSU: Role of Type 2 Inflammation
Dermatology
expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation
Dermatology
expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Shared and Unique Characteristics of AD, PN, and CSU
Dermatology
expert video

Shared and Unique Characteristics of AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU
Dermatology
Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU
Dermatology
expert video

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region